VJHemOnc is committed to improving our service to you

SOHO 2020 | ClonoSEQ: evaluating MRD in CLL

VJHemOnc is committed to improving our service to you

Nitin Jain

Nitin Jain, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the importance of minimal residual disease (MRD) measurement in chronic lymphocytic leukemia (CLL), especially those treated with combination BTK inhibitor and venetoclax. Dr Jain outlines next-generation sequencing assays for MRD, including the ClonoSEQ assay, recently approved for clinical use in CLL patients by the FDA. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter